Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group
- 1 March 2004
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 92 (3) , 949-956
- https://doi.org/10.1016/j.ygyno.2003.12.004
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian CancerJNCI Journal of the National Cancer Institute, 2003
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003
- Docetaxel as neoadjuvant therapy for radically treatablestage III non-small-cell lung cancer: a multinational randomised phase III studyAnnals of Oncology, 2003
- Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancerBritish Journal of Cancer, 2001
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Phase II trials of docetaxel (taxotere®) in advanced ovarian cancer—an updated overviewEuropean Journal Of Cancer, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976
- Creatinine Clearance: Bedside EstimateAnnals of Internal Medicine, 1973